

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

Biology

LLUCC-BIOSPECIMEN
LABORATORY - SPECIMEN
COLLECTION

Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection
Protocol

[Mark E. Reeves, MD, PhD](#)

Brain

SWOG-NRG-BN001

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

<https://clinicaltrials.gov/ct2/show/NCT02179086>

[Joseph Kang, MD](#)

Breast

NSABP-B51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

<https://clinicaltrials.gov/ct2/show/NCT01872975>

[Sharon Lum, MD](#)

SWOG-A011106

ALTErnate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study

<https://clinicaltrials.gov/ct2/show/NCT01953588>

[Gayathri Nagaraj, MD](#)

SWOG-A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

<https://clinicaltrials.gov/ct2/show/NCT01901094>

[Sharon Lum, MD](#)

SWOG-S1207

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

<http://www.clinicaltrials.gov/ct2/show/NCT01674140>

[Gayathri Nagaraj, MD](#)

PUMA-NER-1301

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)

<https://clinicaltrials.gov/ct2/show/NCT01808573>

[Gayathri Nagaraj, MD](#)

YALE University-SHAVE2

A Multicenter Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients

<https://clinicaltrials.gov/ct2/show/NCT02772731>

[Sharon Lum, MD](#)

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

Breast continued

Merck-MK3475-355

A Randomized, Double-Blind, Phase III Study of pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer-(KEYNOTE-355)
<https://clinicaltrials.gov/ct2/show/NCT02819518>

[Gayathri Nagaraj, MD](#)

GI
Colon

SWOG-S0820

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
<http://www.clinicaltrials.gov/ct2/show/NCT01349881>

[Chung-Tsen Hsueh, MD, PhD](#)

GI
Esophagus

Radiation Medicine

A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
<https://clinicaltrials.gov/ct2/show/NCT01684904>

[Gary Yang, MD](#)

Gastric

Investigator Initiated HIPEC

Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer
<https://clinicaltrials.gov/ct2/show/NCT02672865>

[Maheswari Senthil, MD](#)

Liver

Radiation Medicine

Randomized controlled trial of transarterial chemoembolization versus proton beam radiotherapy for the treatment of hepatocellular carcinoma
<https://clinicaltrials.gov/ct2/show/NCT00857805>

[David Bush, MD](#) &
[Michael De Vera, MD](#)

Radiation Medicine

Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases
<https://clinicaltrials.gov/ct2/show/NCT01697371>

[Gary Yang, MD](#)

GI
Pancreas

Radiation Medicine

A phase II trial of gemcitabine and erlotinib (GB) plus proton-chemotherapy (PCT) and capox for locally advanced pancreatic cancer (LAPC)
<https://clinicaltrials.gov/ct2/show/NCT01683422>

[Gary Yang, MD](#)

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies**

GU

Bladder

SWOG-S1314

A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
<https://clinicaltrials.gov/ct2/show/NCT02177695>

[John Wong, MD](#)

GU

Prostate

SWOG-S1216

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
<http://www.clinicaltrials.gov/ct2/show/NCT01809691>

[John Wong, MD](#)

Radiation Medicine

Phase I-II trial of hypofractionated conformal proton beam radiation therapy for favorable-risk prostate Cancer
<https://clinicaltrials.gov/ct2/show/NCT00831623>

[Jerry Slater, MD](#)

Radiation Medicine

Cytogenetic damage as a biomarker of radiation sensitivity in prostate cancer

Marcelo Vazquez , MD, PhD

GU

Testicular

Investigator Initiated-4T-14-1

Phase II Trials of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma with Isolated Retroperitoneal Disease (1-2cm)
<https://clinicaltrials.gov/ct2/show/NCT02537548>

[Brian Hu, MD](#)

GYN

Ovarian

Investigator Initiated HIPEC

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
<https://clinicaltrials.gov/ct2/show/NCT02672098>

[Mazdak Momeni, MD](#)

GYN

Uterus

GOG-0263

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
<https://clinicaltrials.gov/ct2/show/NCT01101451>

[Yevgeniya Ioffe, MD](#)

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

Leukemia

SWOG-S1318	A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF) https://clinicaltrials.gov/ct2/show/NCT02143414	Muhammad Kamal, MD
------------	--	------------------------------------

Lung

Novartis-CLDK378A2112	A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC) https://clinicaltrials.gov/ct2/show/NCT02299505	Hamid Mirshahidi, MD
SWOG-A151216	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) https://clinicaltrials.gov/ct2/show/NCT02194738	Hamid Mirshahidi, MD
SWOG-A081105	Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) https://clinicaltrials.gov/ct2/show/NCT02194738	Hamid Mirshahidi, MD
SWOG-EA5142	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers https://clinicaltrials.gov/ct2/show/NCT02595944	Hamid Mirshahidi, MD
SWOG-E4512	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein https://clinicaltrials.gov/ct2/show/NCT02201992	Hamid Mirshahidi, MD
SWOG-S1400	Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer http://clinicaltrials.gov/ct2/show/NCT02154490	Hamid Mirshahidi, MD
Mirati – 265-109	Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor https://clinicaltrials.gov/ct2/show/NCT02544633	Hamid Mirshahidi, MD

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies**

Lung continued

Xcovery-X396-CLI-101	Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer https://clinicaltrials.gov/ct2/show/NCT01625234	Hamid Mirshahidi, MD
SWOG-S1507	A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies https://clinicaltrials.gov/ct2/show/NCT02642042	Hamid Mirshahidi, MD
Astellas-8273-CL-0302	An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations (SOLAR Study) https://clinicaltrials.gov/ct2/show/NCT02588261	Hamid Mirshahidi, MD
Taiho-TO-TAS-114-201	A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination with S-1 in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer https://clinicaltrials.gov/ct2/show/NCT02025803	Hamid Mirshahidi, MD
Genentech-ML39237	A Phase II Single-arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-small Cell Lung Cancer: Clinical Evaluation of Novel Blood-based Diagnostics https://clinicaltrials.gov/ct2/show/NCT02848651	Hamid Mirshahidi, MD

Melanoma

SWOG-S1320	A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma http://clinicaltrials.gov/ct2/show/NCT02196181	Frank Howard, IV, MD, PhD
------------	---	---

Multiple

BCT-BCT-100-005	Recombinant Human Arginase 1 (rhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety, and PK/PD https://clinicaltrials.gov/ct2/show/NCT02285101	C.S. Chen, MD, PhD
SWOG-EAY131-MATCH	Molecular Analysis for Therapy Choice (MATCH) https://clinicaltrials.gov/ct2/show/NCT02465060	Gayathri Nagaraj, MD

Soft Tissue Sarcoma

Radiation Medicine	A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall https://clinicaltrials.gov/ct2/show/NCT01819831	Gary Yang, MD
--------------------	---	-------------------------------

**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies**

Registry

Radiation Medicine

Radiation Medicine Patient Registry
<https://clinicaltrials.gov/ct2/show/NCT02436941>

[Jerry Slater, MD](#)